(Date:12/2/2009)...ire/ -- S*BIO Pte Ltd today announced data present...t The American Society of Hematology 51st Annual M...ill be presented on the clinical results from the ...its safety, tolerability and pharmacokinetic/pharm...from 100 to 600 mg. These doses were administered ...
(Date:12/2/2009)...FirstCall/ - AEterna Zentaris Inc. (NASDAQ: AEZS ...tical company focused on endocrine therapy and onc... Administration (FDA) has granted Fast Track desig...r compound, perifosine (KRX-0401), for the treatme...Biopharmaceuticals, Inc. ("Keryx") ( KERX), is AEt...
(Date:12/2/2009)...re/ -- According to the National Institute of Heal...d with diabetes already have some stage of diabeti...e retina caused by leaky blood vessels, is a major... one of the most feared diabetic complications. I...d diabetes for 10 years or more will experience so...
(Date:12/1/2009)...re/ -- Reportlinker.com announces that a new marke..., Chromium - Global Market Trends ,, ht...al-Market-Trends.html ,, Worldwide demand for ...l, while growth in aerospace and industrial gas tu...mium metal. Environmental constraints and rapid de...
Breaking Biology Technology:S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 2S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 3S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 4S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 5AEterna Zentaris' Anti-Cancer Compound, Perifosine (KRX-0401), Receives FDA Fast Track Designation for the Treatment of Relapsed/Refractory Multiple Myeloma 2AEterna Zentaris' Anti-Cancer Compound, Perifosine (KRX-0401), Receives FDA Fast Track Designation for the Treatment of Relapsed/Refractory Multiple Myeloma 3Study Shows Pine Bark Improves Microcirculation, Retinal Swelling And Visual Acuity In Early Diabetic Retinopathy 2Study Shows Pine Bark Improves Microcirculation, Retinal Swelling And Visual Acuity In Early Diabetic Retinopathy 3Study Shows Pine Bark Improves Microcirculation, Retinal Swelling And Visual Acuity In Early Diabetic Retinopathy 4Reportlinker Adds Chromium - Global Market Trends 2Reportlinker Adds Chromium - Global Market Trends 3Reportlinker Adds Chromium - Global Market Trends 4Reportlinker Adds Chromium - Global Market Trends 5Reportlinker Adds Chromium - Global Market Trends 6Reportlinker Adds Chromium - Global Market Trends 7Reportlinker Adds Chromium - Global Market Trends 8Reportlinker Adds Chromium - Global Market Trends 9... Efficacy Will Drive Prescription Rates, According...urces, WALTHAM, Mass., Feb. 13 Decision Resource...y firms focusing on pharmaceutical and,healthcare ...y 2009,Centocor/Janssen-Cilag,s ustekinumab will b...2011. Ustekinumab will achieve gold standard statu...
...e Nanotech, Inc.,(OTC Bulletin Board: AVNA), a lea... announced today that at a special meeting of shar... on February 12, 2008, a proposal was,approved to ...l stock from,100,000,000 shares to 225,000,000 sha...the meeting were voted in favor of the proposal to...
... American Country to Approve Treatment, BASINGSTO... 13, Shire plc (LSE: SHP)(NASDAQ: SHPGY )(TSX: SH... announced that ELAPRASE(R),(idursulfase), a human...unter syndrome, has been approved for commercial s...ection against Sanitary Risk (COFEPRIS).,Mexico is...
Other Biology Technology:Centocor/Janssen-Cilag's Ustekinumab Will Become the Gold Standard for Psoriasis By 2011 2Advance Nanotech Announces Shareholder Proxy Vote Results 2Advance Nanotech Announces Shareholder Proxy Vote Results 3Shire's ELAPRASE(R) (idursulfase) Approved in Mexico for Treatment of Hunter Syndrome 2Shire's ELAPRASE(R) (idursulfase) Approved in Mexico for Treatment of Hunter Syndrome 3Shire's ELAPRASE(R) (idursulfase) Approved in Mexico for Treatment of Hunter Syndrome 4...basic components and protocol required to develop ...tation of a specific protein in 100 l/well of cell...oating and Detection Antibodies, Recombinant Stand...B Substrate Solution (one-step) and Stop Solution....
...R) Competitor Assay Kits are ideal for studying or...pounds using fluorescence polarization (FP). The h...ransferase to the ligand binding domain of human p...ry, fluorescently tagged progesterone ligand, Fluo...
Organic Acid Analysis Standard, 6 vials from Bio-Rad
...ging Systems group announces the availability of K...eaturing high resolution cooled CCD camera technol...radiographic and chromogenic imaging capability. T...m lens provides spatial resolution of up to 10 mic...
Biology Products: